Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Healthcare Biotechnology
Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Noxopharm Ltd > Comments from Aurizon CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by MrMonkon Jun 07, 2013 10:37am
123 Views
Post# 21497441

RE: RE: Comments from Aurizon CEO

RE: RE: Comments from Aurizon CEO

I'm not 100% sure of anything - no-one is.  I'm highly confident it will become one and I'm betting my money on it.  There's a 2.1MM ounce resource (with more ounces to come after Phase 2) and that includes a highly conservative capping factor.  Recoveries are excellent and we're surrounded by producing mines (including the largest one in Canada; want to find gold? Search near other, proven deposits that already contain gold) in one of the most prolific and mining-friendly jurisdictions in the world.

Company is well-funded and accessing additional capital will not be difficult if the resources continues to grow and that gold can be pulled out of the ground profitably.  Can't believe so many people are missing all this.

If Hecla/Aurizon don't continue with this, I have little doubt other partners will be lining up and NOX will be able to negotiate a better deal for themselves (and for us) since this is no longer a purely speculative deposit - it has been de-risked to a good degree.

 

-- MM

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities